Patrick Fabbio - 30 Jan 2023 Form 4 Insider Report for Protara Therapeutics, Inc. (TARA)

Role
Chief Financial Officer
Signature
/s/ Mary Grendell, Attorney-in-Fact
Issuer symbol
TARA
Transactions as of
30 Jan 2023
Net transactions value
$0
Form type
4
Filing time
30 Jan 2023, 15:52:23 UTC
Previous filing
23 Dec 2022
Next filing
23 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARA Stock Option (Right to Buy) Award $0 +300,000 $0.000000 300,000 30 Jan 2023 Common Stock 300,000 $3.14 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares shall vest on January 30, 2024 and the remainder of the shares will vest in a series of thirty-six successive equal monthly installments measured from January 30, 2024, subject to the Reporting Person's Continuous Service (as defined in the Company's 2020 Inducement Plan) with the Issuer through each such vesting date.